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Background: Various studies have reported that the emergence of drug-resistant tuberculosis 
poses a significant threat to tuberculosis-control programs worldwide. Rifampicin resistance is 
a surrogate marker of multidrug-resistant tuberculosis, since it reveals the presence of greater 
than 90% isoniazid resistance. Evidence on rifampicin-resistant Mycobacterium tuberculosis 
is scarce in the literature.
Objective: To determine the prevalence of rifampicin-resistant M. tuberculosis among tuber-
culosis-presumptive cases at the University of Gondar Hospital.
Materials and methods: A retrospective study was conducted at the University of Gondar 
Hospital from January 2013 to August 2015. Data were collected from registration books using 
a data-extraction format after securing ethical approval and checking the completeness of nec-
essary information. Data were double-entered and rechecked to ensure accuracy and analyzed 
using SPSS version 20. Results were summarized using descriptive statistics. Associations were 
assessed using Fisher’s exact test, and P<0.05 was considered statistically significant.
Results: A total of 1,820 M. tuberculosis-presumptive patients were included in the study. The 
majority of the study participants were males (59.2%). The mean age of the participants was 
36.6±15.8 years. The preponderant age-group was 24–30 years, with 477 (23.5%) patients. The 
overall prevalence of M. tuberculosis-confirmed cases was 448 (24.6%, 95% CI 0.23–0.27). 
Of the 448 M. tuberculosis-confirmed cases, 71 (15.8%, 95% CI 1.12–1.19) were resistant to 
rifampicin. Rifampicin-resistant M. tuberculosis was observed among HIV seropositives (14 
[18.7%]), males (45[17.3%]), and previously treated tuberculosis patients (61 [16.5%]), although 
no significant association was found in this study.
Conclusion: The overall prevalence of M. tuberculosis and rifampicin resistance was found 
to be high in tuberculosis patients in this study. Therefore, early detection of drug-resistant 
M. tuberculosis should be strengthened for management of tuberculosis patients.
Keywords: University of Gondar Hospital, rifampicin-resistant, tuberculosis
Introduction
Tuberculosis (TB) is a chronic airborne infectious disease caused by the bacillus Myco-
bacterium tuberculosis (MTB). According to a World Health Organization (WHO) 
2016 report, MTB remains a major public health problem, ranking above HIV/AIDS. 
It is one of the leading causes of morbidity and mortality among infectious diseases 
worldwide.1 The best estimate of TB deaths in 2015 was 4 million, with an additional 
0.4 million deaths resulting from TB disease among HIV-positive people. In terms 
of cases, there were 10.4 million new TB cases, of which 5.9 million were men, 3.5 
 million women, and 1 million children detected. Cases that remain undetected continue 
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to suffer from TB disease and also transmit the disease to 
their contacts.1,2
The prevention, diagnosis, and treatment of TB has 
become more complicated because of HIV-associated TB 
and multidrug resistant (MDR) TB. Many people die of TB 
owing to delayed diagnosis, which makes people, mainly 
in the sub-Saharan region, unable to reduce transmission 
significantly, and thus the epidemic continues.3 A global 
TB report estimated that there were about 230,000 (247 
per 100,000 population) incident cases of TB in Ethiopia. 
In the same report, there were about 16,000 deaths (18 per 
100,000) due to TB, excluding HIV-related deaths during the 
same period.4 Ethiopia ranks seventh among the world’s 22 
high-TB-burden countries, 10th among high-TB-pandemic 
countries, and fourth in sub-Saharan Africa.5
Worldwide emergence of MDR-MTB has been reported 
in both developed and developing countries.6 The incidence 
of MDR-TB is increasing, with almost half million estimated 
new cases in 2008.7 Ethiopia is one of the 27 high MDR-
TB countries, ranked 15th with more than 5,000 estimated 
MDR-TB patients each year.8
Globally, the estimated prevalence of MDR-TB was 
3.3% in newly diagnosed patients in the WHO 2015 report. 
This was higher (20%) in patients with a history of anti-TB 
treatment.5 MDR-TB is largely a consequence of poor supply 
management and quality of anti-TB drugs and inadequate or 
improper treatment. which is further worsened by HIV. Recent 
studies have indicated that on average, new HIV-positive TB 
patients are at increased risk of MDR-TB compared with 
HIV-negative patients.1,9,10 Poor infection-control practice 
has also been identified as a major contributing factor in the 
spread of drug-resistant TB.2,3 Based on the 2005 nationwide 
survey in Ethiopia, the prevalence of MDR-TB was 1.6% 
among new cases and 11.8% in the retreatment cases and 
rifampicin resistant was lower than 2% in new cases.11
A history of previous TB treatment is the strongest risk 
factor for progress of MDR-TB. The risk of transmission of 
resistant strains from close contacts is rising, because of the 
growing burden of MDR-TB patients12,13 and extensively DR 
Mycobacterium spp.14
Smear microscopy is widely used for the rapid diagnosis 
of TB, but it does not detect DR-MTB or sensitivity. In indi-
viduals who are coinfected with HIV, the detection rate varies 
between 20% and 50%.15 Results of mycobacterial culture 
turnaround require about 2–8 weeks, though this is not widely 
available in developing countries, including Ethiopia.15,16 
This creates a diagnostic delay that hinders disease control, 
enhances transmission, and increases health-care costs.17
In Ethiopia, TB-case detection is mainly comprised of 
passive case finding, which is able to detect up to two-thirds 
of the annually estimated TB cases. TB screening among 
close and household contacts is one of the new approaches 
recommended by the national TB program to improve TB-
case detection. This is usually carried out by sputum-smear 
microscopy and by GeneXpert MTB/RIF if the index-TB 
case is suspected to be a patient with DR-TB or who is at 
risk of harboring DR-TB.18 The national GeneXpert MTB/
RIF implementation guideline recommends its use among 
presumptive MDR-TB cases that include symptomatic con-
tacts of MDR-TB cases and presumptive TB cases among 
HIV-positive individuals and children below 14 years of age.19
GeneXpert is an automated real-time polymerase 
chain-reaction assay designed for the rapid and simultane-
ous detection of MTB and rifampicin resistance.20–22 Most 
rifampin-resistant MTB-complex strains have mutations in 
an 81-base-pair region of the RPOB gene that encodes the 
RNA polymerase β-subunit. This region is an ideal target for 
molecular tests for rifampin resistance.23 The assay amplifies 
a MTB-complex-specific region of the RPOB gene, which 
is probed with molecular bonfires to detect the presence of 
rifampicin resistance-determining mutations.24
Continuous surveillance of the primary and acquired DR 
patterns of MTB is vital in assessing the efficacy of treatment 
regimens, as well as in detecting problems related to previous 
TB treatments. In Ethiopia, sputum-smear microscopy for 
acid-fast bacilli has been the backbone of TB-case detection 
in the past few decades. However, in developing countries, 
TB-culture and DR testing are not routinely carried out as 
part of the laboratory workup, owing to extreme economic 
disparities, low literacy, and impaired basic health-service 
delivery. Determining the prevalence of rifampicin-resistant 
MTB with advanced technology is critical to prevent drug 
resistance, like MDR-TB and extensively DR-TB. As far 
as the literature is concerned, little work has been done to 
document information systematically on the prevalence of 
rifampicin-resistant MTB using Xpert MTB/RIF in Ethio-
pia, particularly in Gondar. Therefore, this study aimed to 
determine the prevalence of rifampicin-resistant MTB among 
TB-presumptive cases at the University of Gondar Hospital, 
northwest Ethiopia.
Materials and methods
Study design, area, and period
A retrospective cross-sectional study was conducted 
from January 2013 to August 2015 at the University of 
Gondar Hospital TB DOTS (directly observed treatment, 
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short course) Clinic laboratory. the University of Gondar 
Hospital is found in Gondar town. The town is located 
in Amhara National Regional State 727 km from Addis 
Ababa, the capital. It offers a referral service for nearly 
5 million inhabitants in northwest Ethiopia. The study 
population were all TB-presumptive (patients with clinical 
signs and symptoms suggestive of TB) patients who visited 
the hospital during the study period. Patients presumptive 
for pulmonary TB and who had full documentation in the 
registration book were included, whereas patents who had 
incomplete data, eg, age, sex, GeneXpert results, were 
excluded from the study.
Laboratory investigation
The TB DOTS Clinic operates under the national TB- and 
leprosy-control program of Ethiopia, in which the diagnosis 
of TB is followed by Xpert MTB/RIF assay for rifampicin 
resistance. Samples were processed by GeneXpert MTB/
RIF assay. These were diluted and decontaminated, and the 
GeneXpert MTB/RIF assay was performed according to the 
manufacturer’s manual. The Xpert MTB/RIF purifies and 
concentrates MTB bacilli from the samples. Genomic mate-
rial is isolated from the captured bacteria by sonication and 
the genomic DNA subsequently amplified by polymerase 
chain reaction. Furthermore, the process identifies all the 
clinically relevant rifampicin resistance, inducing muta-
tions in the RPOB gene in the MTB genome in a real-time 
format using fluorescent probes called molecular beacons. 
Internal quality controls (sample processing control and 
probe check control) were used during the assay.
HIV testing was done according to the national algorithm 
recommended by the Federal Ministry of Health of Ethiopia. 
Rapid HIV tests – HIV (1 + 2) rapid test strip and Stat-Pak – 
were run sequentially. Positive samples were confirmed with 
Stat-Pak. Discordant results were resolved using a third 
confirmatory testing kit: HIV1/2 Uni-Gold recombinant 
assay. Laboratory procedures were performed according to 
standard operating procedures.
Data collection and analysis
Data were collected retrospectively from registration books 
at the University of Gondar Hospital TB DOTS Clinic using 
a data-extraction format after checking the completeness of 
the data. Seven records of study participants with incom-
plete data and demographic characteristics were excluded 
from 1,827 study participants, resulting in 1,820. Data were 
analyzed using SPSS version 20. Results were summarized 
using descriptive statistics. Association between dependent 
and independent variables were assessed using Fisher’s exact 
test, and P<0.05 was considered statistically significant.
Ethical clearance
Data was collected after ethical clearance had been obtained 
from the School of Biomedical and Laboratory Sciences, Col-
lege of Medicine and Health Science, University of Gondar. 
After discussion of the purpose and aim of the study, permis-
sion was also obtained from the head of the University of 
Gondar Hospital TB clinic prior to data collection. To ensure 
confidentiality of participants’ information, anonymous typ-
ing was used, whereby the name, identification number, and 
any other personal identifiers were not extracted during data 
collection. Also, the data was kept in a confidential manner. 
As secondary data were used, informed consent was not 
sought from the study participants.
Results
Sociodemographic and clinical 
characteristics
This retrospective cross-sectional study was conducted 
with a total of 1,820 presumptive TB cases. Among these, 
742 (40.8%) were females and 1,078 (59.2%) males. The 
majority of the patients, 427 (23.5%), were in the age-group 
24–30 years. Among total study participants, 315 (17.3%) 
were HIV-seropositive, 622 (34.1%) were HIV-seronegative, 
and the remaining 884 (48.6%) had unknown HIV status 
(Table 1).
Mycobacterium tuberculosis by sex  
and age
The overall prevalence of TB was 448 (24.6%, 95% CI 
23%–27%). Based on the Xpert MTB/RIF assay, the highest 
positive finding (29.8%) of TB was observed in the age-group 
24–30 years. The proportion of MTB was 24.1% in males and 
25.3% in females. Rifampicin-resistant MTB was noted in 
71 (3.9%). Based on Fisher’s exact test, positive test results 
were strongly associated with age (P=0.001) (Table 2).
Mycobacterium tuberculosis based on  
HIV status and TB-treatment history
Of the study participants, 315 (17.3%) were HIV-positive. 
HIV-TB coinfection was observed in 75 (23.8%), and 371 
(24.5%) TB cases had a history of TB treatment. However, 
based on Fisher’s exact test, both history of treatment and 
HIV status of the study subjects had no statistical association 
with the positive findings (P>0.05) (Table 2).
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Rifampicin resistant Mycobacterium 
tuberculosis among TB-confirmed study 
participants
Of the 448 (24.6%) TB-confirmed cases, 71(15.8%, 95% CI 
1.12–1.19) were resistant to rifampicin. The proportion of 
MTB was higher 45 (17.3%) in males, and the predominant 
age-groups with rifampicin-resistant TB were 17–23 and 
52–58 years, 16 (24.6%) and five (26.3%), respectively; 75 
(23.8%) of the TB-confirmed subjects were HIV-positive. 
Rifampicin-resistant TB cases among HIV-positive subjects 
numbered 14 (18.7%). Rifampicin-resistant MTB subjects 
numbered 61 (16.4%) among previously treated TB patients 
(Table 3).
Mycobacterium tuberculosis according to 
year of diagnosis
A total of 1,820 study participants were included for Xpert 
MTB/RIF during 2013–2015. Of the participants enrolled, 
Table 1 Sociodemographic and clinical characteristics of the 
study participants
Variables n (total 1,820) Percentage
Sex Male 1,078 59.2
Female 742 40.8
Age-group, years <10 56 3.1
10–16 61 3.4
17–23 252 13.8
24–30 427 23.5
31–37 246 13.5
38–44 238 13.1
45–51 223 12.3
52–58 118 6.5
>58 199 10.9
History of 
treatment
Previously  
treated
1,515 83.2
New cases 305 16.8
HIV status Negative 621 34.1
Positive 315 17.3
Unknown 884 48.6
Year of diagnosis 2013 225 12.4
2014 858 47.1
2015 737 40.5
Table 2 Mycobacterium tuberculosis (MTB) among the study 
participants based on sex, age, history of TB treatment, and HIV 
status
Variables MTB-positive 
cases, n (%)
MTB-negative 
cases, n (%)
Total P-value
Sex 0.55
Male 260 (24.1) 818 (75.9) 1078
Female 188 (25.3) 554 (74.7) 742
Total 448 (24.6) 1372 (75.4) 1820
Age-group, years 0.001
<10 5 (10.2) 44 (89.8) 49
10–16 14 (20.6) 54 (79.4) 68
17–23 65 (25.8) 187 (74.2) 252
24–30 127 (29.8) 300 (70.2) 427
31–37 77 (31.3) 169 (68.7) 246
38–44 47 (19.8) 191 (80.2) 238
45–51 51 (22.9) 172 (77.1) 223
52–58 19 (16.1) 99 (83.9) 118
>58 43 (21.6) 156 (78.4) 199
Total 448 (24.6) 1,372 (75.4) 1,820
TB-treatment history 0.78
Previously 
treated cases
371 (24.5) 1,144 (75.5) 1,515
New cases 77 (25.2) 228 (74.8) 305
Total 448 (24.6) 1,372 (75.4) 1,820
HIV status 0.26
Positive 75 (23.8) 240 (76.2) 315
Negative 167 (26.9) 454 (73.1) 621
Unknown 206 (23.3) 678 (76.7) 884
Total 448 (24.6) 1,372 (75.4) 1,820
Table 3 Rif-resistant MTB among confirmed TB patients based 
on sex, age, treatment history, and HIV status
Variables MTB+/Rif–, 
n (%)
MTB+/Rif+, 
n (%)
Total TB  
positives, n (%)
P-value
Sex 0.32
Male 215 (82.7) 45 (17.3) 260 (58)
Female 162 (86.2) 26 (13.8) 188 (42)
Total 377 (84.2) 71 (15.8) 448 (100)
Age-group, years 0.06
<10 5 (100) 0 5 (1.1)
10–16 13 (92.9) 1 (7.1) 14 (3.1)
17–23 49 (75.4) 16 (24.6) 65 (14.5)
24–30 103 (81.1) 24 (19.9) 127 (28.3)
31–37 67 (87) 10 (13) 77 (17.2)
38–44 45 (95.7) 2 (4.3) 47 (10.5)
45–51 46 (90.2) 5 (9.8) 51 (11.4)
52–58 14 (73.7) 5 (26.3) 19 (4.2)
>58 35 (81.4) 8 (18.6) 43 (10)
Total 377 (84.2) 71 (15.8) 448 (100)
TB-treatment history 0.54
Previously 
treated cases
310 (83.6) 61 (16.4) 371 (82.8)
New cases 67 (87) 10 (13) 77 (17.2)
Total 377 (84.2) 71 (15.8) 448 (100)
HIV status 0.33
Positive 61 (81.3) 14 (18.7) 75 (16.7)
Negative 146 (87.4) 21 (12.6) 167 (37.3)
Unknown 170 (82.5) 36 (17.5) 206 (46)
Total 377 (84.2) 71 (15.8) 448 (100)
Notes: MTB+/RIF–, MTB-positive, but not Rif-resistant. MTB+/RIF+: MTB-positive 
and Rif-resistant.
Abbreviations: MTB, Mycobacterium tuberculosis; Rif, rifampicin.
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448 (24.6%) were positive for TB on GeneXpert, of which 
71 (3.9%) were rifampicin-resistant. The trend in prevalence 
of TB was relatively higher in 2014 (Figure 1).
Discussion
The impact and management of rifampicin-resistant TB 
have not been deeply studied compared to MDR-TB, which 
is well known to be associated with poor TB-treatment out-
come. This study reveals an overall prevalence of TB among 
presumptive cases of 448 (24.6%). This finding is higher 
than the previous studies conducted in southern Ethiopia 
(16.5%, 19.4%).25–27 However, our finding is lower than a 
study conducted in East Gojjam, Ethiopia of 124 (32.2%).28 
A probable reason for this variation might have been that 
we included presumptive cases to identify MTB, while other 
studies included identified cases of TB to check GeneXpert 
differences in study population. The method of diagnosis 
and study setting may account for the variation in prevalence 
across studies.
According to our study, the disease predominated slightly 
among females: 188 (25.3%). This is comparable with a study 
conducted in southern Ethiopia,25 contrary reports from the 
WHO,1,4,5 and a population-based prevalence survey of TB 
in the Tigray region of Ethiopia, which confirmed TB was 
higher among males (352 of 100,000).29 This difference 
in sex incidence might be due to health-seeking behavior, 
 environmental factors, and the higher exposure of males to 
different factors that pose a risk of acquiring the TB bacilli. 
Even if it is difficult to compare with previous reports 
directly, as different studies used different cutoff points for 
age-groups, based on our study result, TB was more prevalent 
among the productive age group of study participants (127 
[29.8%]) and those with rifampicin resistance (16 [24.6%]).
This is in agreement with studies conducted in Yirgalem 
Hospital in southern Ethiopia and the Agaro Teaching Health 
Center in southwestern Ethiopia.25,27 This might be due to 
more exposure to the outer environment, high workload, and 
wide range of mobility in younger age-groups.
We found higher levels of resistance to rifampicin, 71 
(3.9%), among the participants, and 71 (15.8%) among TB 
confirmed cases, almost equivalent (3.4%) to the study con-
ducted in Yirgalem, southern Ethiopia25 and higher than other 
studies conducted in Ethiopia, where resistance was 2.5% 
in the northern, 1.7% in the east, 1.9% (primary resistance) 
in the northwest Ethiopia, and 2.59% in East Gojjam.25,28–34 
This variation might be due to disparities in awareness of 
studied populations about drug resistance, access to health-
care facilities, disorganized patient diagnosis, treatment, 
and follow-up, and poor patient adherence, which may have 
contributed to the higher prevalence of rifampicin-resistant 
TB in our study. The higher level of rifampicin resistance 
might be due to the fact that rifampicin is currently used for 
Figure 1 Rif-resistant MTB based on year of diagnosis.
Notes: MTB+/RIF–, MTB-positive, but not Rif-resistant. MTB+/RIF+: MTB-positive and Rif-resistant.
Abbreviations: MTB, Mycobacterium tuberculosis; Rif, rifampicin.
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the treatment of many other infectious diseases in this study 
area. Since rifampicin is the most vital drug to treat TB, the 
advent of resistance to this drug has enormous implications 
for TB-control programs.
Prevalence in this study was higher than studies conducted 
in South Africa during 2007–2009 with an overall proportion 
of rifampicin resistance 8.8%, studies in Kenya of 6.5%, 
India of 4.69%), and Iran of 7.4%, with an average rate of 
5%–10%.35–38 On the other hand, our finding was lower than 
a study conducted in Nigeria (18.8%),39 but comparable to 
a study conducted in Sudan (15.5%).40 Probable reasons 
for this would be differences in patient selection, sample 
size (small samples could overrepresent the proportion), 
irregular supply of anti-TB drugs, poor TB case management 
(inadequate diagnosis, treatment, and follow-up), and poor 
treatment compliance. Also, rifampicin has several adverse 
effects that could result in patient nonadherence, and hence 
may lead to an increase in resistant strains.
Studies conducted in Iran and Nigeria revealed that 
none of the isolates was resistant to rifampicin alone.41,42 
This might be due to a regular supply of anti-TB drugs and 
adequate diagnosis, treatment, and follow-up of TB patients. 
In the current study, males were more likely to have rifam-
picin resistance (45 [17.3%]). TB rates in South Africa have 
shown higher prevalence in males than in females.35 This 
sex-incidence variation might be associated with high health-
seeking behavior in males.43
Studies around the world have shown significant varia-
tions in the prevalence of resistance to anti-TB drugs in 
patients previously treated for TB. Based on a 2005 nation-
wide survey, Ethiopia is also among the high-TB/HIV-burden 
countries, with a TB-HIV coinfection rate over 10%, with 
MDR-TB prevalence 1.6% and 11.8% among new and 
retreatment cases, respectively, and rifampicin resistance 
lower than 2% in new cases.11 With respect to treatment 
history, the isolates showed different resistance patterns for 
rifampicin 61 (16.5%) for previously treated cases, and the 
remainder were new cases (ten [13%]) from TB-confirmed 
study participants.
Our study showed that there were high levels of drug 
resistance among those previously treated for TB. This 
finding is higher compared to other studies in Kenya, with 
prevalence of resistance of 9.9% and 0 for retreatment and 
new cases, respectively, and Bujumbura, Burundi, with 2% 
from new cases and 15% from previously treated cases,44,45 
East Gojjam (2.59% among new cases, 0 among retreatment 
cases),28 and western India (retreated cases 9% rifampicin-
resistant).46,47 Other studies have reported an association 
between previous history of TB treatment and anti-TB-drug 
resistance.48,49 In addition, a study in Palermo, Italy reported 
a wide heterogeneity among the MTB strains observed, 
which illustrates rapid changes in TB epidemiology.50 This 
indicates the existence of ongoing transmission of DR strains, 
and could indicate weakness in TB prevention and control 
measures, as it is convoyed by resistance to rifampicin in new 
cases as well. This indicates that transmission of MDR-TB 
has a considerable role in this epidemic, and historical high 
frequency of treatment abandonment may contribute toward 
high levels of resistance.
In our study, the overall prevalence of TB was high, and 
the prevalence of HIV-TB coinfection was also high (23.8%). 
Rifampicin resistance in HIV-TB coinfected participants was 
18.7%, which is higher than a 2005 estimate of nationwide 
rifampicin resistance under 2% in new cases.11 A high preva-
lence of rifampicin resistance among isolates from TB-HIV 
coinfected patients has been also reported from Brazil.51 
Resistance to specific anti-TB drugs among HIV-infected 
patients was evident in studies on global resistance rate to 
rifampicin alone (0.2%–9.1%.51 A survey of TB isolates 
collected in the US between 1993 and 1996 documented 
rifampicin monoresistance of 2.6% in HIV-positive cases 
and only 0.2% in HIV-negative cases.52 This might be due to 
HIV infection, which may lead to malabsorption of anti-TB 
drugs, especially rifampicin, with adverse effects leading 
patients to nonadherence and subsequent drug resistance 
and treatment failure. This study tried to assess a heretofore 
untouched area. This is very valuable and instructive, and 
could aid in comprehension for health professionals and 
policy makers to address the problem. Data incompleteness 
and poor document-retention systems were a limitation of 
this study, since it involved secondary data.
Conclusion
The prevalence of MTB and rifampicin resistance were 
high in this study. Therefore, early detection of DR-MTB 
should be strengthened for management of TB patients. HIV-
coinfected and previously treated patients were more likely 
to develop rifampicin resistance. Adequate treatment periods 
and observation of TB cases with strict implementation of 
directly observed treatments should be considered, and the 
HIV status of all patients and duration of treatment needs 
to be documented.
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